An observational study in Lung Transplant Failure, sponsored by University Hospital of Mont-Godinne. Status unknown. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-24.
Sponsored by University Hospital of Mont-Godinne · Observational
PGD is a syndrome characterized by alveolocapillary barrier structural and functional alterations with surfactant inactivation and vascular permeability increase, which cause lung edema, parenchymal infiltrate and progressive hypoxemia.
PGD may be enhanced in lung donor. Inflammatory and structural changes may be present in the lungs before organ recovery and/or after organ preservation. The investigators aim to identify the surfactant protein, inflammatory and structural changes in lung donor before and after cold ischemia, and biomarkers to PGD in lung recipients.
Primary graft dysfunction (PGD) is responsible of high early mortality in lung transplanted patients.
Rationale
The evolution of lung transplantation may be complicated by primary graft dysfunction (PGD), a form of acute respiratory distress syndrome caused by ischemia-reperfusion-related phenomena. PGD occurs in 15-50% of cases and is responsible for a significant increase in mortality, duration of assisted ventilation and length of stay in intensive care. It is also an important risk factor for the medium-term development of acute and long-term rejection, of bronchiolitis obliterans syndrome (BOS) - chronic rejection - which drastically reduces the survival of the graft.
Surfactant proteins comprising the secretory protein of Clara cells (16-kd Clara cell protein-CC16) and surfactant proteins -A (SP-A), -B (SP-B) and -D (SP- D) are recognized as markers of the permeability of the alveolocapillary barrier.
Based on these findings, we postulate that the gene expression of CC16, SP-A, -B and D is altered in pulmonary biopsies performed in donors of patients developing primary graft dysfunction after pulmonary transplantation compared to those performed in the donors of patients free of this syndrome.
This study could therefore be a complementary means of objective assessment of lung quality prior to transplantation.
Aims and Objectives
Material and method
Inclusion Criteria
All lung organ donor patients referred to our network and their recipients will be included after obtaining their informed consent.
Data Collection
In the donor, we will record demographic data (age, sex), history, cause of death, blood gas measurement, chest x-ray protocol, blood biological parameters, duration of brain death if appropriate and hot ischemia time if appropriate and protocol of bacteriological analyzes.
In the recipient, we will record the demographic data (age, sex), indication of transplantation, results of right catheterization performed on pre-transplantation, standard intraoperative data, immunosuppression, Blood gas, chest x-ray protocol, filling balance and blood biological parameters at 24, 48 and 72h. The declamping times are recorded.
Patients are automatically followed up for the rest of their lives. Iterative biopsies are performed in the first year to detect possible acute rejection. The data will be included in our study.
Biological samples
In the donor, before the perfusion of the preservation solutions, 18 cc of peripheral blood are taken (dry tube, 9 cc). 1 tube will be stored at -80 ° C., the other will be centrifuged (15 minutes, 10000 / min, 20 ° C.) and then the serum will be stored at -80 ° C.
Immediately after lung recovery, a pulmonary biopsy (6 cm2) is performed at the lower lobes.
A fragment will be immediately placed in liquid nitrogen and stored at -80 ° C. A second fragment is stored in formalin for 24h and then stored in paraffin blocks.
Before implantation, at the end of the preservation period, a new lung biopsy is performed in the lower lobes.
Biological analyzes
Histological examination and gradation
Lung tissues fixed in formalin are stained with hematoxylin-eosin to gradate lung lesions [(1) neutrophil infiltration, (2) airway epithelial cell damage, (3) interstitial edema, (4) Hyaline membrane and (5) hemorrhage].
Inflammation, apoptosis and Surfactant proteins
O Tissue mRNA measurements: in real time Quantification PCR (RTQ-PCR)
O Tissue peptide measurements: Western Blot - ELISA - MILLIPLEX
O Treatment of blood samples and analyzes: ELISA - MILLIPLEX
Protein inflammatory cytokines (TNF-alpha, IL-6, IL-8, IL-1, IL33) (IL-10), intercellular adhesion molecules (ICAM-1, VCAM-1), apoptosis (Bax, Bcl2, Caspases)
Evaluation of apoptosis: TUNEL - Immunohistochemistry
All lung donors and their lung recipients who reached the criteria for lung recovery and transplantation
Exclusion Criteria:
in the first 72 hours following lung transplantation, the lung recipients have blood gases and chest X-Ray to assess the occurrence of primary graft dysfunction. Chest X-Ray infiltrate and pathological PaO2/FiO2 ratio describe PGD occurence
Diagnostic Test: lung biomarkers in organ donor for PGD in lung recipient
In the first 72 hoours following lung transplantation, if the Cest X-ray is normal, the patient is considered PGD-free
Diagnostic Test: lung biomarkers in organ donor for PGD in lung recipient
Lung biopsies in organ donor before and after cold ischemia
Lung Biomarkers for primary graft dysfunction in organ donors
The investigators aim te describe lung donor structural and molecular changes in relation of PGD occurrence in recipient.
Time frame: 5-7 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital of Mont-Godinne